AC
SYRE icon

Aristides Capital’s Spyre Therapeutics SYRE Stock Holding History

Aristides Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,431
Closed -$170K – 286
2021
Q4 		$170K Buy
+1,431
New +$226K 0.08% 217

Other funds holding SYRE

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Aristides Capital's SYRE Position: Q1 2022 in Review

Aristides Capital sold out of Spyre Therapeutics (SYRE) in Q1 2022, closing a stake of 1,431 shares — an estimated $170K sold.

Aristides Capital first reported a position in SYRE in Q4 2021 and held it in 1 quarter. The position peaked at $170K in Q4 2021. 83 funds tracked by Wall St. Rank hold SYRE as of Q1 2022.

  • Aristides Capital reported no remaining Spyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Aristides Capital sold 1,431 Spyre Therapeutics shares in Q1 2022, an estimated $170K.
  • Aristides Capital first reported a position in Spyre Therapeutics in Q4 2021 and held it in 1 quarter.
  • Aristides Capital's Spyre Therapeutics position peaked at $170K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.